Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Biomarkers in early cancer drug development: limited utility.

Glassman RH, Ratain MJ.

Clin Pharmacol Ther. 2009 Feb;85(2):134-5. doi: 10.1038/clpt.2008.231. Review.

PMID:
19151638
2.

Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?

Ratain MJ, Glassman RH.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6545-8. No abstract available.

3.

Wall Street's perspective on oncology drug development.

Glassman RH.

Clin Adv Hematol Oncol. 2007 May;5(5):369-71, 385. No abstract available.

PMID:
17673892
4.

Biotechnology: identifying advances from the hype.

Glassman RH, Sun AY.

Nat Rev Drug Discov. 2004 Feb;3(2):177-83. doi: 10.1038/nrd1309. Review. No abstract available.

PMID:
15040581
5.

v-Crk, an effector of the nerve growth factor signaling pathway, delays apoptotic cell death in neurotrophin-deprived PC12 cells.

Glassman RH, Hempstead BL, Staiano-Coico L, Steiner MG, Hanafusa H, Birge RB.

Cell Death Differ. 1997 Jan;4(1):82-93.

6.

The SH3 domain of Crk binds specifically to a conserved proline-rich motif in Eps15 and Eps15R.

Schumacher C, Knudsen BS, Ohuchi T, Di Fiore PP, Glassman RH, Hanafusa H.

J Biol Chem. 1995 Jun 23;270(25):15341-7.

Supplemental Content

Loading ...
Support Center